Global Blood Viscometer Market Size, Forecast, and Trend Highlights Over 2025-2037
Blood Viscometer Market size is projected to grow from USD 1.78 billion to USD 3.04 billion by 2037, witnessing a CAGR of over 4.2% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of blood viscometer is estimated at USD 1.84 billion.
The rising patient pool with blood disorders is propelling the need for blood viscometers. Presently, 33,000 males suffer from hemophilia in the U.S., while a large base of children also develop the disease by the age of two. 69.7% with genetic predisposition develop the condition within 1 month and 2.8% get it in the prenatal stage. Individuals with the condition are living longer and have fewer complications, owing to NCBDDD data of 74,000 patients at over 140 hemophilia treatment centers in the U.S. The government and other institutional bodies work in close collaboration to promote healthcare facilities and reduce inequities among patients.
NCBDDD Budget Allocation, in 2023
|
Budget Line |
Allocation (in USD million) |
|
Hemophilia Treatment Centers |
5.1 |
|
Public Health Approach to Blood Disorders |
4.4 |
|
Hemophilia |
3.5 |
|
Thalassemia |
2.1 |
|
Sickle Cell Research |
6.0 |
|
Total |
21.1 |
Source: CDC
Furthermore, the CDC, NCBDDD has an upcoming discretionary grant for promoting self-management to mitigate blood disorder community and related mortality using evidence-based programs, commencing September 2025. The program funding is estimated at USD 3,555,000, with an award floor of USD 150,000 and an award ceiling of USD 450,000. In terms of patient care and benefits, before obtaining care, consumers can better understand the cost of a covered good or service thanks to health plan price transparency. Pricing information for covered goods and services is being posted by the majority of group health plans and individual or group health insurance issuers as of July 1, 2022. Third parties, such as academics and app developers, can utilize this pricing information to assist consumers in better understanding the costs of their medical treatment.
HRSA allocated USD 52 million for cell transplantation and cord blood stem cell bank systems, whereas the NIH funded the National Heart, Lung, and Blood Institute with USD 3,985 million in 2024. To drive accessibility of blood disorder treatment and other healthcare services, the Centers for Medicare & Medicaid Services (CMS) has set hospital price transparency under the Public Health Service Act. Similarly, in July 2024 CMS issued a proposed rule that solicits public comments as part of the Physician Fee Schedule (PFS) on proposed policy changes for Medicare payments. Reporting for Value in Primary Care MIPS Value Pathway (MVP) would begin in 2026 based on the calendar year 2025 performance.
Pricing Comparison of Blood Disorder Treatments (2024)
|
Blood Disorder Product Group |
AAC (non-340B) (a) |
WAC (b) |
AWP (c) |
Medicare Allowable |
|
ADVATE |
$1.30525 |
$1.90000 |
$2.28000 |
$1.54800 |
|
ADYNOVATE |
$1.86360 |
$2.49000 |
$2.99000 |
$2.09500 |
|
AFSTYLA |
$1.06632 |
$1.90000 |
$2.28000 |
$1.46000 |
|
ALPHANATE |
$0.90983 |
$1.34000 |
$1.61000 |
$1.22500 |
|
ALPHANINE |
$1.03688 |
$1.69000 |
$2.03000 |
$1.40900 |
|
ALPROLIX |
$3.22113 |
$3.74000 |
$4.49000 |
$3.59100 |
|
ALTUVIIIO |
$4.34871 |
$5.26000 |
$6.31000 |
$4.69400 |
|
BENEFIX |
$1.50882 |
$1.70000 |
$2.04000 |
$1.85200 |
|
COAGADEX |
$8.23971 |
$11.38000 |
$13.66000 |
$9.11200 |
Source: Medicaid
Blood Viscometer Market: Growth Drivers and Challenges
Growth Drivers
- Exponential growth in global medical equipment trade: Medical instruments held a world trade value of USD 167 billion in 2023, contributing to 0.74% of the trade share, and registered a growth rate of 7.85% between 2022-2023. Medical instruments are a part of photo & film equipment, viscometers, needles, catheters, cannula, electro-diagnostic apparatus, syringes, tubular metal needles, electro-cardiographs, dental drill engines, and UV or infra-red ray apparatus. In 2023, the key medical instrument exporters included the U.S. (USD 34.8 billion), Germany (USD 18.4 billion), Mexico (USD 17.6 billion), China (USD 12.3 billion), and Netherlands (USD 9.38 billion).
The medical devices and supplier sector was projected at USD 128.1 million in 2022, which has persistently provided positive prospects for U.S. exporters in Honduras. The industry is highly dependent on imports, is price sensitive, and U.S. medical products reap high receptivity among domestic healthcare providers. According to the International Trade Administration, the outbound trade of medical devices in the U.S. has experienced a 25% spike over the past three years. Pharmaceutical product imports have also witnessed a positive trend, at a projected USD 600 million in 2022. - Rising government initiatives in blood disorders: Governments are supporting clinical trials to bring novel solutions to the blood viscometer market. NHLBI started accepting applications for early phase clinical trials for HLBS disorders intended for diagnostics or therapeutics in April 2024. Moreover, in September 2023, the Inter-American Development Bank (IDB) granted USD 150 million in debt to strengthen the hospital network in Honduras. The program seeks to improve the effectiveness and access to specialized child hospital and maternal services and care for injuries of external causes and non-communicable diseases.
Challenge
- High cost of blood viscometers: Adoption of blood viscometers may be significantly hampered by their cost, especially in environments with limited resources. Healthcare facilities may have financial difficulties due to the high capital expenditure to develop these devices as well as the necessity for ongoing maintenance and calibration, which may restrict market expansion.
Blood Viscometer Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.2% |
|
Base Year Market Size (2024) |
USD 1.78 billion |
|
Forecast Year Market Size (2037) |
USD 3.04 billion |
|
Regional Scope |
|
Blood Viscometer Segmentation
End user (Hospitals, Clinics)
The hospitals segment is projected to account for a 65% share of the global blood viscometer market by the end of 2037. Blood viscometers in hospitals have a widespread use case to precisely and rapidly obtain blood type information such as blood group typing, thus enabling healthcare providers to make prompt and accurate decisions. According to a July 2022 report by the National Library of Medicine, high-shear BV (eHSBV) and low-shear BV were associated with elevated in-hospital mortality, respectively 36.0% and 7.0% rise in death. COVID-19 sparked abnormal blood rheology leading to thrombotic complications and endothelial dysfunction. Whole blood viscosity (WBV) has been identified as a clinically validated predictor of cardiovascular risks and a measure of blood rheology in hospital settings.
Type (Rotational Viscometer, Capillary Viscometer)
The rotational viscometer segment in blood viscometer market is anticipated to hold the largest revenue share of about 68% during the forecast period. Rotational viscometers are pivotal in bio-medical labs and clinical studies to test glycerol–water mixtures with various densities using optical coherence tomography (OCT) measurement method. It is also a standard treatment procedure and therapeutic apheresis for HVS management, among patients with hyper-viscosity of the plasma and immunoglobulin reduction. Rotational viscometers have resulted in a shift from conventional rituximab- and alkylator-based, and purine nucleoside analog-based therapies, which usually take months to show the best response.
Our in-depth analysis of the global blood viscometer market includes the following segments:
|
Type |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBlood Viscometer Industry - Regional Synopsis
North America Market Forecast
North America blood viscometer market is expected to hold the largest revenue share of 30% by 2037. The region has a large patient pool, with hemophilia A and B affecting 3,900 people in Canada. Additionally, 300,000 people have inherited bleeding disorder genes, contributing to CVD incidences. In 2024, 89,190 lymphoma cases were registered in the U.S. and 62,770 were leukemia. The U.S. heavily invests in Medicare and related infrastructure to support social security and healthcare accessibility. 14.3% or USD 423 million of the FY2025 obligated U.S. budget of USD 3 trillion has been allocated to Medicare, signifying the country’s potential for future growth.
In 2023, the U.S. supplied USD 34.8 billion worth of medical instruments, making it the exporter globally. In the same year, medical instruments emerged as the 11th most supplied item from the country. The primary destinations were the Netherlands (USD 5.91 billion), China (USD 3.26 billion), Germany (USD 3.17 billion), Mexico (USD 3.15 billion), and Japan (USD 2.8 billion). In November 2024, the medical instruments outbound trade amounted to USD 3 billion and imports USD 3.42 billion, resulting in a trade deficit of USD 412 million. Between November 2023 and November 2024, the outbound supply increased by USD 22.1 million (0.74%), i.e. from USD 2.98 billion to USD 3 billion, while imports surged by USD 60.1 million (1.79%), i.e. from USD 3.36 billion to USD 3.42 billion. In November 2024, the primary recipients of medical instruments were Netherlands (USD 515 million), Mexico (USD 355 million), Canada (USD 278 million), China (USD 277 million), and Japan (USD 222 million).
Europe Market Statistics
Blood viscometer market in Europe is anticipated to hold the second-largest revenue share of about 25% during the forecast period. Europe has positioned itself as a major contributor to the worldwide trade of medical devices, including blood viscometers. Germany and Ireland were among the top five exporters, valuing USD 341 million and USD 266 million, finds OEC. The November 2024 sure in medical device year-by-year exports can be explained primarily by growth in demand in the Netherlands (USD 128 million, at 36.1% share). Moreover, Ireland accounted for 22% of the overall trade, positioning Europe as a key contender in the blood viscometer market.
Germany’s government spending as a share of GDP was 31.5% in 2023, whereas the spending on healthcare was a staggering 12.65%. The presence of a robust, yet self-governing insurance system facilitates the blood viscometer market growth in the nation. In matters concerning social or public health coverage, the Federal Joint Committee (G-BA) holds the primary decision-making abilities, in support of the Institute for Quality Assurance and Transparency in Health Care (IQTIG) and the Institute for Quality and Efficiency in Health Care (IQWiG).
Companies Dominating the Blood Viscometer Landscape
- Benson Viscometers Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioFluid Technology Inc.
- Thermo Fisher Scientific
- RheoSense
- Anton Paar GmbH
- China BeiJing Steellex Scientific Instrument Co.
- Scientific Instrument Co. Ltd.
- Health Onvector
- Cambridge Viscosity
- AMETEK Inc.
In the News
- In August 2024, Ametek Brookfield declared that HPQA (Helipath Quick Action Stand) is now fully integrated with DVPlus viscometer. This has raised the standard of efficiency and precision in the viscosity testing.
- In January 2023, Anton Paar launched a rotational Viscometer with modern features such as magnetic coupling, digital levelling, etc. These unique features prevent operator error, ensuring reliable viscosity cost efficiently.
Author Credits: Radhika Pawar
- Report ID: 5474
- Published Date: Mar 07, 2025
- Report Format: PDF, PPT
